Study reveals high efficacy of Sputnik V in protecting aged 60+ against COVID

pharmafile | November 1, 2021 | News story | Sales and Marketing  

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) has announced the results of a real world study by the Ministry of Health in Buenos Aires, Argentina, which has confirmed high efficacy of the Russian Sputnik V vaccine in protecting individuals aged at least 60 years.

The study included over 660,000 individuals in Buenos Aires who were aged at least 60 years, vaccinated with Sputnik V, AstraZeneca, or Sinopharm vaccines. Sputnik V was found to be the most common in terms of the number of vaccinated individuals in the study: more than 63% of participants were fully vaccinated with Sputnik V.

Results of the study have shown that infection rates decreased for over 88% among those who received the full vaccination against COVID. The full vaccination led to a 96.6% reduction in mortality. 

The full vaccination was also associated with a 94.2% reduction of all-cause deaths among those aged at least 80 years, and a 98.2% among those aged 70 to 79 years. 

Back in June, a study by the Ministry of Health in Buenos Aires demonstrated that the first component of the Sputnik V vaccine (the single-shot Sputnik Light vaccine) had 78.6-83.7% efficacy among persons aged 60-79 years. 

The Sputnik V has played a crucial role in the immunisation programme in Buenos Aires, and is one of the main vaccines used during the vaccination campaign throughout Argentina. It provides for 35 times reduction in new COVID cases during four months. 

Despite the results of this promising study, Sputnik V has struggled to attain international regulatory approval.  

Lina Adams


Related Content

No items found

Latest content